Morphosys Ag (MOR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MorphoSys AG has announced a delisting agreement with Novartis, following the latter’s successful acquisition and intent to merge with MorphoSys. Novartis, now holding over 91% of MorphoSys shares, plans to offer the remaining shareholders €68.00 per share to consolidate ownership. The transaction processes, including the delisting from Frankfurt Stock Exchange and NASDAQ, are expected to be completed in the third quarter of 2024.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.